<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology, clinical features, and types of small bowel neoplasms
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology, clinical features, and types of small bowel neoplasms
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology, clinical features, and types of small bowel neoplasms
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael J Overman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hiroko Kunitake, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth K Tanabe, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of small bowel tumors is often difficult due to the rarity of these lesions and the nonspecific and variable nature of the presenting signs and symptoms. Thus, delay in diagnosis is common, which may result in the discovery of disease at a late stage and a poor treatment outcome.
        </p>
        <p>
         Several tumors can arise within the small bowel, both malignant (adenocarcinomas, neuroendocrine tumors, lymphomas, and sarcomas) and benign (adenomas, leiomyomas, lipomas). Epidemiology, clinical manifestations, and specific tumor types will be reviewed here. Diagnosis, staging, and management of small bowel tumors are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2516.html" rel="external">
          "Diagnosis and staging of small bowel neoplasms"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2509.html" rel="external">
          "Treatment of small bowel neoplasms"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          TYPES OF TUMORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of tumors, both malignant and benign, may arise within the small intestine.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Malignant tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The distribution of histologic types of small bowel malignant tumors is changing, largely because of the increasing incidence of neuroendocrine (carcinoid) tumors (NETs). In 1987, the most common histologic types of malignant tumors of the small intestine in population-based registry data from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute (NCI) were adenocarcinoma 45 percent, NET 29 percent, lymphoma 16 percent, and sarcoma 10 percent [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         In the year 2000, NETs surpassed adenocarcinomas as the most common small bowel tumor reported to the National Cancer Database (NCDB) [
         <a href="#rid2">
          2
         </a>
         ]. Between 1985 and 2005, the proportion of patients with NETs increased from 28 to 44 percent, while the proportion of adenocarcinoma decreased from 42 to 33 percent. The proportion of patients with stromal tumors and lymphoma remained essentially stable (17 and 8 percent, respectively).
        </p>
        <p>
         Although these malignancies may be found throughout the different regions of the intestine, certain subtypes have a predilection for specific regions [
         <a href="#rid1">
          1,3
         </a>
         ]. Adenocarcinoma is the most common malignancy affecting the duodenum, and NET is the most common tumor in the ileum, while sarcomas and lymphomas can develop throughout the entire small bowel [
         <a href="#rid2">
          2,4
         </a>
         ]. The distribution of tumor subtypes according to small bowel location in a combined analysis of data from three registry-based series (the NCDB [1985 to 2005] and United States SEER [1973 to 2005] cohorts, and the Connecticut Tumor Registry [1980 to 2000] [
         <a href="#rid5">
          5-7
         </a>
         ]) is depicted in the figure  (
         <a class="graphic graphic_figure graphicRef109933" href="/z/d/graphic/109933.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Largely as a result of these differences in distribution, the reported relative incidence of each histology varies considerably with the patient population under study [
         <a href="#rid5">
          5,9,10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Benign lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Benign lesions that may arise in the small bowel include adenomas, hamartomas, leiomyomas, fibromas, and lipomas [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following sections will discuss general aspects of the epidemiology of small bowel tumors. Specific epidemiologic aspects of the individual tumor types are discussed below.
        </p>
        <p>
         Malignancies involving the small intestine are rare. In the United States, there are approximately 12,000 new cases and 2000 deaths from small bowel cancer annually [
         <a href="#rid12">
          12
         </a>
         ]. Although the small intestine represents approximately 75 percent of the length and over 90 percent of the surface area of the alimentary tract, small bowel malignancies account for approximately 3 percent of all gastrointestinal tract neoplasms [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p>
         By contrast, over 150,000 new cases of large bowel cancer are diagnosed each year in the United States [
         <a href="#rid12">
          12
         </a>
         ]. Several theories, based upon the unique microenvironment of the small intestine, have been proposed to explain the low rate of small bowel neoplasms relative to large bowel cancer [
         <a href="#rid1">
          1,14
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The more dilute and liquid contents of the small bowel may cause less mucosal irritation than the more solid contents of the colon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The relatively rapid transit of intestinal contents through the small bowel may provide for a shorter exposure to carcinogens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The much lower bacterial load (particularly anaerobic bacteria) in the small bowel may result in less conversion of bile acids into potential carcinogens by anaerobic organisms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Benzpyrene, a known carcinogen present in food, is converted to less toxic metabolites by benzpyrene hydroxylase, which is present in higher concentrations in the small intestine compared with the stomach and colon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The increased lymphoid tissue and secretory immunoglobulin A (IgA), found in large quantities in the small bowel, may be protective.
        </p>
        <p>
        </p>
        <p>
         While rates of large bowel cancer have been stable or decreasing over time, the incidence of small bowel cancer appears to be increasing, at least in the United States [
         <a href="#rid2">
          2,5,6,15-17
         </a>
         ]. In older studies, reported age-adjusted incidence rates of small bowel cancer ranged from 1 to 3 per 100,000 population [
         <a href="#rid4">
          4,9,16
         </a>
         ]. However, in a study analyzing the Connecticut Tumor Registry, a marked rise in the incidence of small bowel tumors over time was noted, with an incidence in the most recent time interval (1994 to 2000) of 14.8 cases per 100,000 population [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         The degree to which the increased incidence is related to advances in diagnostic imaging is not known. However, much of the increase appears to be driven by a rising incidence of small bowel neuroendocrine tumors (NETs) [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2613.html" rel="external">
          "Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts", section on 'Epidemiology'
         </a>
         and
         <a class="local">
          'Malignant tumors'
         </a>
         above.)
        </p>
        <p>
         The mean age at diagnosis of a small bowel neoplasm is 65 years old, with sarcoma and lymphoma presenting at a slightly younger age (60 to 62) than adenocarcinoma and NETs (67 to 68) [
         <a href="#rid5">
          5,10
         </a>
         ]. There is a slight male predominance (male to female ratio of 1.5:1 [
         <a href="#rid16">
          16
         </a>
         ]), and a number of studies report a higher incidence in Black than in White patients [
         <a href="#rid1">
          1,16
         </a>
         ].
        </p>
        <p>
         As a general rule, patients with small bowel adenocarcinoma have a higher incidence of secondary malignancies involving the colon, rectum, ampulla of Vater, endometrium, and ovary [
         <a href="#rid18">
          18,19
         </a>
         ]. Conversely, patients with colon adenocarcinoma have an increased risk of small bowel adenocarcinoma [
         <a href="#rid20">
          20
         </a>
         ]. These findings suggest that similar underlying genetic or environmental factors are involved in the carcinogenesis of adenocarcinomas arising in both the small and large intestine. A number of known heritable cancer syndromes are associated with adenocarcinoma of both the large and small bowel, including hereditary nonpolyposis colorectal cancer (HNPCC), familial adenomatous polyposis (FAP), and Peutz-Jeghers syndrome. (See
         <a class="local">
          'Pathogenesis, risk factors, and predisposing conditions'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          PATHOGENESIS, RISK FACTORS, AND PREDISPOSING CONDITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The etiology of most small bowel tumors is unknown, although a number of risk factors and predisposing conditions have been described.
        </p>
        <p class="headingAnchor" id="H2663876368">
         <span class="h2">
          Adenocarcinoma
         </span>
        </p>
        <p class="headingAnchor" id="H2150399480">
         <span class="h3">
          The adenoma-carcinoma sequence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most small bowel adenocarcinomas arise from adenomas, and the available data suggest an adenoma-carcinoma sequence driven by a multistep process of specific genetic changes similar to that described for colorectal cancers, but less well documented or understood  (
         <a class="graphic graphic_figure graphicRef91173" href="/z/d/graphic/91173.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid8">
          8,21
         </a>
         ]. Single, specific germline mutations underlie some common inherited syndromes (eg, familial adenomatous polyposis [FAP], hereditary nonpolyposis colorectal cancer [HNPCC]), while sporadic cancers result from the stepwise accumulation of multiple somatic mutations, possibly acquired as a result of exposure to carcinogens within the intestinal lumen. (See
         <a class="medical medical_review" href="/z/d/html/2485.html" rel="external">
          "Molecular genetics of colorectal cancer"
         </a>
         .)
        </p>
        <p>
         As is seen in colon cancer, the increasing size of adenomas and the presence of villous features are both risk factors for the development of invasive carcinoma within an adenoma [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2594.html" rel="external">
          "Overview of colon polyps"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2951729565">
         <span class="h4">
          Molecular profiling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increasingly, biomarker expression is driving therapeutic decision making in patients with advanced refractory cancer. Small bowel adenocarcinomas have a different genomic profile compared with colorectal and gastric adenocarcinomas, including variations in the frequency and types of alterations of
         <em>
          KRAS
         </em>
         , adenomatosis polyposis coli (
         <em>
          APC
         </em>
         ),
         <em>
          BRAF
         </em>
         , human epidermal growth factor receptor 2 (
         <em>
          ERBB2
         </em>
         /
         <em>
          HER2
         </em>
         ),
         <em>
          ERBB3
         </em>
         , and other genes [
         <a href="#rid23">
          23,24
         </a>
         ]. These variations might be contributing to the disparities in outcomes among these tumor types, and they also might provide some opportunity for targeted therapeutics in this disease. (See
         <a class="medical medical_review" href="/z/d/html/2509.html" rel="external">
          "Treatment of small bowel neoplasms", section on 'Molecular profiling and targeted therapies'
         </a>
         .)
        </p>
        <p>
         In one report, a total of 7559 patients (317 small bowel adenocarcinomas, 889 gastric carcinomas, and 6353 colorectal cancers) were analyzed on either a 236 or 315 cancer-related gene panel by Foundation Medicine, and alterations were compared across these three tumor types.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The main differences in the frequency of genomic alterations between small bowel adenocarcinoma and colorectal cancer were in the
         <em>
          APC
         </em>
         (26.8 percent in small bowel versus 75.9 percent in colorectal cancer, p&lt;0.001) and cyclin-dependent kinase inhibitor 2A (
         <em>
          CDKN2A
         </em>
         ; 14.5 percent in small bowel versus 2.6 percent in colorectal cancer, p&lt;0.001) genes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The main differences between small bowel adenocarcinoma and gastric cancer were in
         <em>
          KRAS
         </em>
         (53.6 percent in small bowel versus 14.2 percent in gastric cancer, p&lt;0.001),
         <em>
          APC
         </em>
         (26.8 versus 7.8 percent, p&lt;0.001), and mothers against decapentaplegic homolog 4 (
         <em>
          SMAD4
         </em>
         ; 17.4 versus 5.2 percent, p&lt;0.001).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Molecular differences between small bowel subsites (duodenum, jejunum, ileum) were minimal, suggesting common genomic features across the small bowel.
        </p>
        <p>
        </p>
        <p>
         In a separate report, exome sequencing performed on 106 primary small bowel adenocarcinomas demonstrated four mutational signatures: signature 6, associated with mismatch repair (MMR) deficiency; signature 1A, associated with older age; and signatures 17 and U2, two signatures of unknown cause [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         These efforts demonstrate small bowel adenocarcinomas to have their own molecular profile differing from other neighboring gastrointestinal tract cancers.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Hereditary cancer syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         An increased risk of adenocarcinoma is seen in a number of familial cancer syndromes, many of which are linked to specific inherited genetic abnormalities:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HNPCC is an inherited condition characterized by loss of DNA MMR, which is caused by a germline mutation in one allele of a MMR gene and inactivation of the second allele by mutation, loss of heterozygosity, or epigenetic silencing by promoter hypermethylation. The biologic footprint of deficient DNA MMR is high levels of microsatellite instability (MSI-H). Affected individuals are at risk for colorectal cancer and for several extracolonic cancers, including adenocarcinomas of the small bowel and endometrium. As with colorectal cancer, HNPCC is thought to be responsible for approximately 5 to 10 percent of small bowel adenocarcinomas [
         <a href="#rid25">
          25,26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">
          "Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Peutz-Jeghers syndrome is an autosomal dominant polyposis disorder characterized by multiple hamartomatous polyps throughout the intestinal tract and a marked increase risk for adenocarcinoma of both the large and small bowel [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">
          "Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         FAP is associated with a germline mutation in the
         <em>
          APC
         </em>
         gene that promotes tumor formation in primarily the large intestine but also the duodenum. These patients have multiple duodenal polyps (with a predilection for the ampullary region), which can undergo malignant transformation into an adenocarcinoma. In addition, patients with FAP are predisposed to the development of desmoid tumors, which develop within the small bowel or its mesentery and are often multiple in number  (
         <a class="graphic graphic_diagnosticimage graphicRef54879" href="/z/d/graphic/54879.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid28">
          28,29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7746.html" rel="external">
          "Desmoid tumors: Epidemiology, molecular pathogenesis, clinical presentation, diagnosis, and local therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2593.html" rel="external">
          "Clinical manifestations and diagnosis of familial adenomatous polyposis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/644.html" rel="external">
          "Ampullary adenomas: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Dietary factors, tobacco, and obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of dietary factors have been associated with an increased risk of a small bowel cancer in case-control studies, including intake of alcohol, refined sugar, red meat, and salt-cured and smoked foods [
         <a href="#rid14">
          14,17,30,31
         </a>
         ]. Tobacco use was associated with cancer risk in two studies, while others suggest no increased risk in smokers [
         <a href="#rid30">
          30,32,33
         </a>
         ]. Studies on the relationship between obesity and small bowel malignancy are conflicting, with some showing an increased risk in obese patients [
         <a href="#rid34">
          34-36
         </a>
         ], some a decreased risk [
         <a href="#rid33">
          33
         </a>
         ], and others no effect [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2833553063">
         <span class="h3">
          Cystic fibrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with cystic fibrosis have an elevated risk of small bowel cancer. In a meta-analysis, the pooled standardized incidence ratio was 18.94, 95% CI 9.37-38.27, and it was two- to fivefold higher following lung transplantation [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5858.html" rel="external">
          "Cystic fibrosis: Overview of gastrointestinal disease", section on 'Gastrointestinal cancer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3182602869">
         <span class="h2">
          Chronic inflammation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A role for chronic inflammation in the etiology of both adenocarcinoma and lymphoma is suggested by the fact that small bowel disorders characterized by chronic mucosal inflammation predispose to malignancy. Inflammatory bowel disease, in particular Crohn disease, predisposes to adenocarcinoma within the involved area of the small intestine. The risk increases with both the extent and duration of small bowel involvement [
         <a href="#rid38">
          38-40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"
         </a>
         .)
        </p>
        <p>
         An increased risk of small bowel lymphoma is seen in patients with chronic immunodeficiency states and autoimmune disorders, including celiac disease [
         <a href="#rid41">
          41,42
         </a>
         ]. Patients with celiac disease also have a higher risk for small bowel adenocarcinoma [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">
          "Clinical presentation and diagnosis of primary gastrointestinal lymphomas"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">
          "Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2126566887">
         <span class="h2">
          Neuroendocrine tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis and risk factors for neuroendocrine tumors arising in the small bowel are almost entirely unknown, apart from an association with multiple endocrine neoplasia type I (MEN-I) in rare cases [
         <a href="#rid44">
          44,45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">
          "Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The general aspects of the clinical presentation of benign and malignant small bowel tumors are discussed here. Specific symptoms associated with individual tumor types are discussed below. (See
         <a class="local">
          'Types of tumors'
         </a>
         above.)
        </p>
        <p>
         The most common presenting symptom of a small bowel tumor is abdominal pain, which is present in 44 to 90 percent of patients [
         <a href="#rid46">
          46-49
         </a>
         ]. Pain is typically intermittent and crampy in nature. Weight loss occurs in 24 to 44 percent, nausea and vomiting in 17 to 64 percent, and gastrointestinal bleeding in 23 to 41 percent. Intestinal obstruction is more common than perforation, occurring in 22 to 26 percent compared with 6 to 9 percent, respectively [
         <a href="#rid46">
          46-48
         </a>
         ].
        </p>
        <p>
         As compared with those with benign tumors, patients with malignant small bowel neoplasms are more often symptomatic, and the majority of symptomatic small bowel tumors are malignant [
         <a href="#rid46">
          46,50
         </a>
         ]. Furthermore, symptoms at presentation tend to differ between benign and malignant tumors. As an example, in a report of 49 patients with a small bowel neoplasm (17 benign and 32 malignant), 47 percent of benign tumors were asymptomatic (versus 6 percent of malignant tumors), and when symptomatic, they more commonly presented with acute gastrointestinal hemorrhage (29 versus 6 percent of malignant tumors). Malignant tumors more commonly presented with abdominal pain (63 versus 24 percent) and weight loss (38 versus 0 percent). Despite these data, clinical presentation alone does not permit the distinction between a benign versus a malignant lesion.
        </p>
        <p>
         The often vague and nonspecific nature of the symptoms makes early diagnosis of a malignant small bowel tumor difficult. There may be a significant delay from onset of symptoms to diagnosis (in one series, averaging 30 weeks [
         <a href="#rid46">
          46
         </a>
         ]). As a result, by the time a patient becomes symptomatic, their disease is usually advanced, with either involvement of regional lymph nodes or distant metastatic sites.
        </p>
        <p>
         The differential diagnosis is broad given the nonspecific symptoms. More common causes of small bowel stricturing or obstruction include adhesions, hernia entrapment, inflammatory bowel disease, endometriosis, splenosis, and complications from appendicitis or diverticulitis.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          ADENOCARCINOMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adenocarcinomas represent from 25 to 40 percent of primary small bowel malignancies [
         <a href="#rid1">
          1,2,5,9,10,49,51
         </a>
         ]. They usually present between the ages of 50 to 70, and there is a slight male predominance. Age of onset tends to be lower in patients with predisposing conditions, such as Crohn disease [
         <a href="#rid25">
          25,27,52,53
         </a>
         ].
        </p>
        <p>
         As noted above, the risk of small bowel adenocarcinoma is higher in patients who have had colorectal cancer, suggesting a possible common etiology [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
         Also as noted above, inherited syndromes, such as hereditary nonpolyposis colorectal cancer (HNPCC) or familial adenomatous polyposis (FAP), are responsible for fewer than 10 percent of small bowel adenocarcinomas [
         <a href="#rid54">
          54,55
         </a>
         ]. Patients with HNPCC are at increased risk for adenocarcinoma throughout the small bowel, while FAP increases the risk for both adenomas and adenocarcinomas of the duodenum. (See
         <a class="local">
          'Hereditary cancer syndromes'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Location
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of adenocarcinoma is highest in the duodenum  (
         <a class="graphic graphic_picture graphicRef62067" href="/z/d/graphic/62067.html" rel="external">
          picture 1
         </a>
         ) and decreases progressively throughout the rest of the small intestine. In two large single-institution series of patients with small bowel adenocarcinoma, 65 and 57 percent of cases arose in the duodenum [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p>
         Explanations for the predilection to the initial part of the small bowel include the metabolism or dilution of ingested carcinogens in transit through the small bowel or interactions of carcinogens with pancreaticobiliary secretions [
         <a href="#rid58">
          58
         </a>
         ]. The possible etiologic role of pancreaticobiliary secretions is supported by a study evaluating 213 cases of duodenal adenocarcinoma identified from the Los Angeles County Tumor Registry, in which the exact subsite within the duodenum was identified. Fifty-seven percent of cases occurred in the second portion of the duodenum, consistent with a primarily periampullary distribution [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Crohn disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         An exception to the predominantly proximal location is in patients with Crohn disease. Seventy percent of adenocarcinomas that arise in this setting are in the ileum, the primary site of the inflammatory process. (See
         <a class="medical medical_review" href="/z/d/html/4079.html" rel="external">
          "Surveillance and management of dysplasia in patients with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
         The development of an adenocarcinoma in patients with Crohn disease should be suspected in those with longstanding disease who develop a change in their clinical status, such as an obstruction that fails to resolve with usual medical treatments [
         <a href="#rid59">
          59,60
         </a>
         ]. The risk for adenocarcinoma is directly related to both the extent of small bowel involvement and the duration of Crohn disease. In one report, the cumulative risk of a small bowel adenocarcinoma in patients with small bowel Crohn disease was 0.2 percent at 10 years and 2.2 percent at 25 years [
         <a href="#rid61">
          61
         </a>
         ]. The diagnosis is rarely made preoperatively since the symptoms are similar to those of Crohn disease with an inflammatory or fibrous stricture [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Presenting symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation of adenocarcinoma of the small bowel is nonspecific, with the most frequent symptom being abdominal pain. In a series of 491 patients with small bowel adenocarcinoma, presenting symptoms were as follows [
         <a href="#rid57">
          57
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdominal pain – 43 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nausea and vomiting – 16 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anemia – 15 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overt gastrointestinal tract bleeding – 7 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Jaundice – 6 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight loss – 3 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other or no symptoms – 9 percent
        </p>
        <p>
        </p>
        <p>
         An obstructed duodenal adenocarcinoma may present with vomiting due to a gastric outlet obstruction, while in those with more distal lesions, severe cramping abdominal pain may be the presenting symptom. Intestinal obstruction can be caused by progression of an apple core lesion  (
         <a class="graphic graphic_diagnosticimage graphicRef58561" href="/z/d/graphic/58561.html" rel="external">
          image 2
         </a>
         ) or by a large intraluminal polypoid mass.
        </p>
        <p>
         Largely because of the vague nature of symptoms, the majority of patients have advanced disease (stage III or IV  (
         <a class="graphic graphic_table graphicRef110785" href="/z/d/graphic/110785.html" rel="external">
          table 1
         </a>
         )) at diagnosis. In a large series of patients with small bowel adenocarcinoma derived from the National Cancer Database (NCDB), the distribution of stage at diagnosis was as follows [
         <a href="#rid62">
          62
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage 0 – 3 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage I – 12 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage II – 27 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage III – 26 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage IV – 32 percent
        </p>
        <p>
        </p>
        <p>
         The diagnostic and staging evaluation and treatment of small bowel adenocarcinoma is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2516.html" rel="external">
          "Diagnosis and staging of small bowel neoplasms"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          NEUROENDOCRINE TUMORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuroendocrine tumors (NETs) of the small bowel have a morphologically unique appearance and are characterized by the production of biologically active amines, which are stored in neurosecretory granules. Secretion of these products by the tumor cells can result in a variety of clinical syndromes caused by the secreted product:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The vast majority are well-differentiated (grade 1 or 2) gastrointestinal NETs (GINETs), previously termed carcinoid tumors  (
         <a class="graphic graphic_table graphicRef60365" href="/z/d/graphic/60365.html" rel="external">
          table 2
         </a>
         ). Carcinoid syndrome is the term applied to a constellation of symptoms mediated by various humoral factors elaborated by some well-differentiated NETs of the digestive tract and lungs, which synthesize, store, and release a variety of polypeptides, biogenic amines, and prostaglandins  (
         <a class="graphic graphic_table graphicRef79329" href="/z/d/graphic/79329.html" rel="external">
          table 3
         </a>
         ). Some of these tumor products are responsible for carcinoid syndrome, but the relative contributions of each and the specificity of any for particular components of the syndrome are uncertain  (
         <a class="graphic graphic_table graphicRef63079" href="/z/d/graphic/63079.html" rel="external">
          table 4
         </a>
         ). More than 90 percent of patients with carcinoid syndrome have metastatic disease from a small bowel primary NET, typically to the liver. (See
         <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">
          "Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on '2010 and 2019 World Health Organization classification'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2614.html" rel="external">
          "Clinical features of carcinoid syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2622.html" rel="external">
          "Diagnosis of carcinoid syndrome and tumor localization"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other functioning NETs of the small bowel that produce specific clinical syndromes are rare when compared with these well-differentiated GINETs. The most common is a gastrinoma of the duodenum, which is defined by the associated clinical syndrome of excess gastrin secretion (Zollinger-Ellison syndrome). Although the majority of gastrinomas, 85 percent, are localized to the pancreas, approximately 15 percent will be found in the upper duodenum. (See
         <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">
          "Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other even more rarely reported NETs arising in the small bowel include duodenal somatostatinomas, paragangliomas, and high-grade (poorly differentiated) neuroendocrine carcinomas, which are rarely, if ever, functioning  (
         <a class="graphic graphic_table graphicRef60365" href="/z/d/graphic/60365.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">
          "Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on '2010 and 2019 World Health Organization classification'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2608.html" rel="external">
          "Somatostatinoma: Clinical manifestations, diagnosis, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">
          "High-grade gastroenteropancreatic neuroendocrine neoplasms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Well-differentiated gastrointestinal neuroendocrine tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most GINETs arising in the small bowel are typically well-differentiated (grade 1 or 2  (
         <a class="graphic graphic_table graphicRef111125" href="/z/d/graphic/111125.html" rel="external">
          table 5
         </a>
         )) NETs, most of which are characterized by an indolent disease course [
         <a href="#rid63">
          63
         </a>
         ]. Notably, duodenal NETs may have a more heterogenous disease course, with a high rate of metastasis both at the time of diagnosis and following resection, even if well differentiated [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         In modern series, NETs represent approximately 40 percent of primary small intestinal malignancies [
         <a href="#rid2">
          2,5,9,10
         </a>
         ]. They have been reported in patients from 20 to 80 years old, with the highest incidence in the 60s.
        </p>
        <p>
         Grossly, these tumors appear as firm intramucosal or submucosal nodules, with a yellow cut surface due to their high lipid content. They tend to infiltrate the bowel wall and may extend through the serosa, causing shortening and thickening of the mesentery due to an intense associated desmoplastic reaction  (
         <a class="graphic graphic_diagnosticimage graphicRef78186" href="/z/d/graphic/78186.html" rel="external">
          image 3
         </a>
         ). Microscopically, solid nests of uniform small cells with round or oval nuclei are present with a surrounding intense desmoplastic reaction  (
         <a class="graphic graphic_picture graphicRef77795" href="/z/d/graphic/77795.html" rel="external">
          picture 2
         </a>
         ). They demonstrate little or no cellular pleomorphism, hyperchromasia, or increased mitotic activity. (See
         <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">
          "Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system"
         </a>
         .)
        </p>
        <p>
         Small bowel well-differentiated GINETs are most commonly found in the ileum, within 60 cm of the ileocecal valve. The presence of multiple synchronous nodules in 30 percent of patients mandates careful inspection of the entire small intestine to exclude other sites of disease [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         Because of their indolent growth, most well-differentiated small bowel GINETs are asymptomatic at presentation (ie, there are no symptoms of local obstruction or carcinoid syndrome) and found only incidentally. Symptoms generally relate to mass effects from the primary or metastatic tumors, or they may be caused by tumor production of bioactive amines (carcinoid syndrome):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most common syndrome caused by tumor production of bioactive amines is carcinoid syndrome, which usually does not occur until the bioactive amines have gained access to the systemic circulation (typically in the setting of liver metastases). The most common symptoms are watery diarrhea and flushing. (See
         <a class="medical medical_review" href="/z/d/html/2614.html" rel="external">
          "Clinical features of carcinoid syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In symptomatic patients who do not have carcinoid syndrome, abdominal pain is the most common initial symptom, occurring in approximately 40 percent [
         <a href="#rid55">
          55
         </a>
         ]. The pain is most often vague and nonspecific. Intermittent obstruction occurs in 25 percent of all small intestinal well-differentiated GINETs. Obstruction may be caused by intraluminal tumor, but often results from mesenteric kinking and distortion brought on by tumor invasion and a secondary desmoplastic response [
         <a href="#rid65">
          65
         </a>
         ]. The latter produces a characteristic radiographic abnormality: a combination of abrupt angulation with a filling defect in the small bowel  (
         <a class="graphic graphic_diagnosticimage graphicRef60836" href="/z/d/graphic/60836.html" rel="external">
          image 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pain may also arise from vascular compromise secondary to large bulky mesenteric nodal metastasis, mesenteric vascular invasion, and/or microvascular metastasis. Possibly contributing to the ischemic process is the vasospastic effect of serotonin produced by the tumor (see below).
        </p>
        <p>
        </p>
        <p>
         Metastatic disease, which is present in 90 percent of symptomatic patients with carcinoid syndrome, correlates not only with the depth of invasion and location, but also the size of the primary lesion. For NETs &lt;1 cm, the risk of distant metastasis is 0 to 2 percent for appendiceal as compared with 15 to 18 percent for small bowel primaries. In contrast, once NETs exceed 2 cm, 47 percent of small bowel primaries will have metastasized to liver; lungs and bone are affected less frequently  (
         <a class="graphic graphic_table graphicRef82306" href="/z/d/graphic/82306.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
         The current (2017) Tumor, Node, Metastasis (TNM) classification and staging of small bowel NETs (as adopted by the American Joint Committee on Cancer [AJCC], the Union for International Cancer Control [UICC] [
         <a href="#rid66">
          66
         </a>
         ], and the European Neuroendocrine Tumor Society [ENETS] [
         <a href="#rid67">
          67
         </a>
         ]) includes separate staging tables for NETs of the duodenum/ampulla  (
         <a class="graphic graphic_table graphicRef111095" href="/z/d/graphic/111095.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid68">
          68
         </a>
         ] and tumors arising in the jejunum and ileum  (
         <a class="graphic graphic_table graphicRef111096" href="/z/d/graphic/111096.html" rel="external">
          table 8
         </a>
         ) [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         The clinical characteristics of well-differentiated small bowel GINETs are addressed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2613.html" rel="external">
          "Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts", section on 'Jejunoileal small bowel tumors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Carcinoid syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Well-differentiated GINETs are characterized by their ability to secrete serotonin and other bioactive products  (
         <a class="graphic graphic_table graphicRef79329" href="/z/d/graphic/79329.html" rel="external">
          table 3
         </a>
         ); the majority of patients with carcinoid syndrome have metastatic disease, typically involving the liver. This is because symptoms are most common when the secretory products of these tumors gain direct access to the systemic circulation, thus avoiding metabolism in the liver. This scenario occurs most commonly in the presence of hepatic metastases. (See
         <a class="medical medical_review" href="/z/d/html/2614.html" rel="external">
          "Clinical features of carcinoid syndrome", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p>
         However, at least some data support the view that carcinoid syndrome might be more common in locoregional disease than previously thought. This was illustrated in a population-based series of 9512 GINETs arising in individuals aged 65 or over and derived from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database [
         <a href="#rid70">
          70
         </a>
         ]. Among patients with small bowel primary NETs, the rates of carcinoid syndrome at diagnosis for patients with localized, regional, and distant disease were 155 of 817 (19 percent), 248 of 670 (37 percent), and 242 of 436 (56 percent), respectively. These data suggest that unappreciated hepatic metastases or carcinoid syndrome in locoregional disease may be more common than previously reported [
         <a href="#rid71">
          71-73
         </a>
         ], especially in small bowel primaries.
        </p>
        <p>
         The most common symptoms associated with carcinoid syndrome are watery diarrhea and flushing  (
         <a class="graphic graphic_table graphicRef63079" href="/z/d/graphic/63079.html" rel="external">
          table 4
         </a>
         ). The flush is often dramatic and manifests as an intense purplish color on the upper body and arms; it can be precipitated by consuming alcohol, blue cheese, chocolate, or red wine or with exercise. Repeated attacks can lead to the development of telangiectasias and permanent skin discoloration. (See
         <a class="medical medical_review" href="/z/d/html/2614.html" rel="external">
          "Clinical features of carcinoid syndrome"
         </a>
         .)
        </p>
        <p>
         A life-threatening form of carcinoid syndrome called carcinoid crisis is usually precipitated by a specific event, such as anesthesia, surgery, or chemotherapy. The manifestations include an intense flush, diarrhea, tachycardia, hypertension or hypotension, bronchospasm, and alteration of mental status. Prevention and management are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16638.html" rel="external">
          "Treatment of the carcinoid syndrome", section on 'Carcinoid crisis: prevention and management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          PRIMARY GASTROINTESTINAL TRACT LYMPHOMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lymphoma may arise as a primary neoplasm in the intestinal tract or as a component of systemic disease with gastrointestinal (GI) involvement. The diagnosis of a primary GI lymphoma requires the following [
         <a href="#rid74">
          74
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No peripheral or mediastinal lymphadenopathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A normal white blood cell count and differential on the peripheral blood smear
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor involvement must be predominantly in the GI tract
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No evidence of liver or spleen involvement [
         <a href="#rid75">
          75,76
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Primary GI tract lymphoma is the most common extranodal form of lymphoma; the stomach and small bowel are the most common sites. As an example, in a study of 371 patients registered in a German multicenter treatment study for GI lymphomas, the following sites were involved [
         <a href="#rid77">
          77
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">
          "Clinical presentation and diagnosis of primary gastrointestinal lymphomas"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stomach – 75 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small bowel (including duodenum) – 9 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ileocecal region – 7 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More than one GI site – 6 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rectum – 2 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse colonic involvement – 1 percent
        </p>
        <p>
        </p>
        <p>
         In the Middle East, 75 percent of GI lymphomas originate in the small bowel and are associated with immunoproliferative small intestinal disease (IPSID); synonyms include Mediterranean lymphoma and alpha heavy chain disease. By contrast, small intestinal lymphomas are less common in industrialized nations and are not of the IPSID type. (See
         <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">
          "Clinical presentation and diagnosis of primary gastrointestinal lymphomas"
         </a>
         .)
        </p>
        <p>
         In the United States, small bowel lymphoma occurs predominantly in adults, peaking in the seventh decade, and 60 percent of patients are male [
         <a href="#rid78">
          78
         </a>
         ]. Some of the predisposing conditions include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune diseases
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunodeficiency syndromes (eg, acquired immunodeficiency syndrome [AIDS])
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Long-standing immunosuppressive therapy (eg, post-transplantation)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Crohn disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiation therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nodular lymphoid hyperplasia
        </p>
        <p>
        </p>
        <p>
         The incidence of primary intestinal lymphoma in the United States doubled between 1985 and 1990 [
         <a href="#rid79">
          79
         </a>
         ]. Among the factors implicated in this increase are the increasing number of immunocompromised patients (eg, AIDS, transplantation recipients) and the increasing immigration from resource-limited countries.
        </p>
        <p>
         Lymphomas arise from the lymphoid aggregates in the submucosa. The distribution of lymphoma in the small intestine parallels the distribution of lymphoid follicles, with the lymphoid-rich ileum representing the most common location. As with sarcoma, lymphomas are characteristically bulky tumors; approximately 70 percent are larger than 5 cm in diameter at presentation.
        </p>
        <p>
         Most patients present with abdominal pain, anorexia, and weight loss  (
         <a class="graphic graphic_table graphicRef68593" href="/z/d/graphic/68593.html" rel="external">
          table 9
         </a>
         ). Less commonly, infiltration of the mucosa can result in ulceration and bleeding, and extension to the serosa and adjacent tissues may result in a large obstructing mass with or without intussusception and crampy abdominal pain  (
         <a class="graphic graphic_diagnosticimage graphicRef75825 graphicRef64048" href="/z/d/graphic/75825.html" rel="external">
          image 5A-B
         </a>
         ). The risk of perforation depends on the site of GI tract involvement; perforation is seen in 9 percent of small bowel lymphomas and only 2 percent of gastric lymphomas [
         <a href="#rid77">
          77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">
          "Clinical presentation and diagnosis of primary gastrointestinal lymphomas"
         </a>
         .)
        </p>
        <p>
         Histologically, these non-Hodgkin lymphomas may be low or high grade, and they may be of B-cell or T-cell origin. The Revised European-American Lymphoma (REAL)/World Health Organization (WHO) classification system, as is used for other non-Hodgkin lymphomas, is predominantly used for classification [
         <a href="#rid80">
          80,81
         </a>
         ], although an alternative classification system for primary GI lymphomas has been proposed [
         <a href="#rid82">
          82
         </a>
         ]. The B-cell lymphomas that most often involve the GI tract consist of the mucosa associated lymphoid tissue (MALT) type, diffuse large B-cell, mantle cell, and Burkitt and Burkitt-like variants. MALT type tumors occur most often in the stomach, while mantle cell lymphoma has a predilection for the colon and small intestine. The less common T-cell lymphomas are most often jejunal. Primary or secondary involvement of the GI tract by Hodgkin lymphoma is extremely rare [
         <a href="#rid83">
          83
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">
          "Clinical presentation and diagnosis of primary gastrointestinal lymphomas"
         </a>
         .)
        </p>
        <p>
         Histologic and clinical factors associated with prognosis include histological subtype of non-Hodgkin lymphoma, histologic grade of differentiation, stage of disease, and International Prognostic Index (IPI). (See
         <a class="medical medical_review" href="/z/d/html/4710.html" rel="external">
          "Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SARCOMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malignant mesenchymal tumors (sarcomas) represent approximately 10 percent of small bowel neoplasms [
         <a href="#rid1">
          1,5,10,49,62,84
         </a>
         ] and are most common in the jejunum, the ileum, and a Meckel's diverticulum [
         <a href="#rid85">
          85
         </a>
         ]. The most common type of intestinal sarcoma is gastrointestinal stromal tumor (GIST), accounting for 83 to 86 percent of cases [
         <a href="#rid2">
          2,86
         </a>
         ].
        </p>
        <p>
         Prior to the identification of GISTs by their molecular characteristics, leiomyosarcomas represented the most common small bowel sarcoma. However, the majority of these previously classified leiomyosarcomas in older studies are actually GIST tumors. In a report of 1091 tumors originally classified as "smooth muscle tumors of the small intestine," 906 (83 percent) were GISTs [
         <a href="#rid86">
          86
         </a>
         ]. Among the 176 non-GISTs, there were 53 sarcomas (mostly phenotypically undifferentiated), 32 leiomyosarcomas (3 percent of the total), 13 leiomyomas, 14 sarcomatoid epithelial neoplasms, 13 desmoids, 8 schwannomas, and a variety of other unusual benign and malignant proliferations. (See
         <a class="medical medical_review" href="/z/d/html/7745.html" rel="external">
          "Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors"
         </a>
         .)
        </p>
        <p>
         Histologically, GISTs can have a similar morphologic appearance to leiomyosarcomas  (
         <a class="graphic graphic_picture graphicRef51522" href="/z/d/graphic/51522.html" rel="external">
          picture 3
         </a>
         ) and, thus, must be differentiated based on the expression of c-kit (the CD117 antigen), which represents a component of the KIT tyrosine kinase receptor. Activating mutations in the
         <em>
          KIT
         </em>
         oncogene are seen in over 80 percent of all GISTs. A subset of GISTs lacking
         <em>
          KIT
         </em>
         mutations have activating mutations in a related receptor tyrosine kinase, the platelet derived growth factor receptor alpha (PDGFRA). (See
         <a class="medical medical_review" href="/z/d/html/2516.html" rel="external">
          "Diagnosis and staging of small bowel neoplasms", section on 'Histology and differential diagnosis'
         </a>
         .)
        </p>
        <p>
         Common presenting symptoms of small bowel sarcomas, including GISTs, include pain, weight loss, bleeding, perforation, or a palpable mass [
         <a href="#rid87">
          87
         </a>
         ]. Because they tend to enlarge extraluminally, obstruction is rare and typically a late-presenting symptom.
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          METASTATIC LESIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Secondary neoplastic involvement of the small intestine is more common than is primary small intestinal neoplasia, given the rarity of small bowel neoplasms. Extraluminal involvement of the small bowel is particularly common in the setting of widespread peritoneal carcinomatosis. Erosion through the bowel wall into the lumen can occur, particularly with tumors that have a predilection to involve the peritoneal cavity, such as ovarian, colon, and gastric cancer.
        </p>
        <p>
         Hematogenous spread to the bowel is also possible. In studies in which direct extension from peritoneal metastases was excluded, the most common tumors to hematogenously spread to the small bowel were melanoma, lung, breast, cervix, sarcoma, and colon [
         <a href="#rid88">
          88-90
         </a>
         ]. The small bowel is the most common site of gastrointestinal metastases in patients with metastatic melanoma  (
         <a class="graphic graphic_diagnosticimage graphicRef78537" href="/z/d/graphic/78537.html" rel="external">
          image 6
         </a>
         ) [
         <a href="#rid91">
          91,92
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/131562.html" rel="external">
          "Metastatic melanoma: Surgical management", section on 'Gastrointestinal tract'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          BENIGN TUMORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The frequency of benign tumors of the small bowel increases from the duodenum to the ileum [
         <a href="#rid93">
          93
         </a>
         ]. Of the various histologic types, adenomas, leiomyomas, and lipomas are the most common.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Adenomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are three major types of benign small bowel adenomas: simple villous, tubular, and Brunner's gland adenomas.
        </p>
        <p>
         Villous adenomas carry a significant potential for malignant transformation. Malignant cells are found in as many as 42 percent of duodenal villous adenomas [
         <a href="#rid94">
          94
         </a>
         ], with an adenoma-carcinoma sequence comparable to that of colorectal cancer [
         <a href="#rid95">
          95
         </a>
         ]. Familial adenomatous polyposis (FAP) is a risk factor; 80 percent of affected patients develop duodenal adenomas, which are often multiple [
         <a href="#rid96">
          96
         </a>
         ]. Adenomas in the duodenum have a predilection for the papilla (ampulla of Vater). (See
         <a class="medical medical_review" href="/z/d/html/644.html" rel="external">
          "Ampullary adenomas: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2592.html" rel="external">
          "Familial adenomatous polyposis: Screening and management of patients and families"
         </a>
         .)
        </p>
        <p>
         Coincident colonic adenomas are common in patients who have villous adenomas of the papilla or duodenum, suggesting that colonoscopy is an important component of the diagnostic workup. The usual presentation is with bleeding or obstruction of either the small bowel or biliary tract. On biopsy, the superficial part of the lesion may appear benign, with areas of adenocarcinoma in the deeper parts [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
         Tubular adenomas have a lower malignant potential. They are most common in the duodenum, and are usually asymptomatic, but may present with bleeding or obstruction.
        </p>
        <p>
         There are no firm guidelines regarding the management of sporadic duodenal adenomas, though many gastroenterologists will remove them endoscopically in the absence of endoscopic features suggesting possible malignancy. Additionally, there are no definitive guidelines regarding the size of endoscopically resectable adenomas; however, most authors recommend that lesions ≥4 cm should not be treated endoscopically [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
         Endoscopic retrograde cholangiopancreatography, endoscopic ultrasound, intraductal ultrasound, and chromoendoscopy can all provide useful information in the evaluation of ampullary adenomas, including the extent of intraductal progression of the adenoma. (See
         <a class="medical medical_review" href="/z/d/html/649.html" rel="external">
          "Ampullary adenomas: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/655.html" rel="external">
          "Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging", section on 'Endoscopic ultrasonography'
         </a>
         .)
        </p>
        <p>
         Patients with sporadic duodenal adenomas should also be screened for colorectal cancer as they are at increased risk for colorectal neoplasia [
         <a href="#rid98">
          98-100
         </a>
         ].
        </p>
        <p>
         A Brunner's gland adenoma is a rare small bowel neoplasm. It is caused by hyperplasia of the exocrine glands within the proximal duodenal mucosa. (See
         <a class="medical medical_review" href="/z/d/html/644.html" rel="external">
          "Ampullary adenomas: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5806055">
         <span class="h2">
          Leiomyomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Leiomyomas are single, firm, gray or white, well-defined masses that arise in the submucosal layer of the wall of the small intestine  (
         <a class="graphic graphic_diagnosticimage graphicRef53060" href="/z/d/graphic/53060.html" rel="external">
          image 7
         </a>
         ). Microscopically, they consist of well-differentiated smooth muscle cells  (
         <a class="graphic graphic_picture graphicRef72432" href="/z/d/graphic/72432.html" rel="external">
          picture 4
         </a>
         ). These tumors usually enlarge extraluminally and, therefore, are not detected until they outgrow their blood supply, causing central necrosis, ulceration, and bleeding into the bowel lumen.
        </p>
        <p>
         In cases in which the tumor extends intraluminally, obstruction may be the initial symptom  (
         <a class="graphic graphic_picture graphicRef60327" href="/z/d/graphic/60327.html" rel="external">
          picture 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/8037.html" rel="external">
          "Etiologies, clinical manifestations, and diagnosis of mechanical small bowel obstruction in adults"
         </a>
         .)
        </p>
        <p>
         Leiomyomas are rare; in the series described above, they accounted for only 13 of the 1091 tumors originally classified as smooth muscle tumors of the small intestine (approximately 1 percent) [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Lipomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipomas are the second most common benign tumor arising in the small bowel, and they occur mostly in the ileum and duodenum. They arise from either submucosal adipose tissue or serosal fat and may present with obstruction, small bowel bleeding, or as an incidental finding. These are submucosal lesions with homogeneous fatty tissue on a cut surface. They have a diagnostic low attenuation appearance on computed tomography (CT) scan  (
         <a class="graphic graphic_diagnosticimage graphicRef68559 graphicRef80114" href="/z/d/graphic/68559.html" rel="external">
          image 8A-B
         </a>
         ) [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Other benign lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Desmoid tumors, which are commonly seen in patients with FAP, may grow intraluminally, causing obstruction or, extraluminally, presenting as a palpable abdominal mass  (
         <a class="graphic graphic_diagnosticimage graphicRef54879" href="/z/d/graphic/54879.html" rel="external">
          image 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7746.html" rel="external">
          "Desmoid tumors: Epidemiology, molecular pathogenesis, clinical presentation, diagnosis, and local therapy"
         </a>
         .)
        </p>
        <p>
         Hemangiomas are rare lesions that usually present with bleeding. Hamartomas of the small intestine are seen in patients with the Peutz-Jeghers syndrome. (See
         <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">
          "Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5805264">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A variety of tumors, both malignant and benign, may arise within the small intestine. The most common malignant tumors are well-differentiated neuroendocrine tumors (NETs), adenocarcinomas, lymphomas, and sarcomas. Benign lesions that may arise in the small bowel include adenomas, leiomyomas, fibromas, and lipomas. (See
         <a class="local">
          'Types of tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignancies involving the small intestine are rare; they account for only 2 percent of all gastrointestinal tract neoplasms and fewer than 0.4 percent of all cancers in the United States. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The etiology of most small bowel cancers is unknown, although a number of risk factors and predisposing conditions have been described, particularly for small bowel adenocarcinomas. (See
         <a class="local">
          'Hereditary cancer syndromes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most common presenting symptom of a small bowel tumor is abdominal pain, which is typically intermittent and crampy in nature. Other symptoms include weight loss, nausea and vomiting, gastrointestinal bleeding, and intestinal obstruction. As compared with those with benign tumors, patients with malignant small bowel neoplasms are more often symptomatic, and the majority of symptomatic small bowel tumors are malignant. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The incidence of adenocarcinoma is highest in the duodenum. The most common clinical presentation is abdominal pain; a duodenal adenocarcinoma may present as a gastric outlet obstruction. (See
         <a class="local">
          'Adenocarcinoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Well-differentiated gastrointestinal NETs arising in the small bowel are most commonly found in the ileum, within 60 cm of the ileocecal valve. Because of their indolent growth, most are asymptomatic at presentation and found incidentally. When present, symptoms generally relate to mass effects, including intermittent obstruction. Tumor production of bioactive amines results in carcinoid syndrome (watery diarrhea, flushing, sweating, wheezing, dyspnea, abdominal pain, hypotension) only when the secretory products gain direct access to the systemic circulation, thus avoiding metabolism in the liver; this occurs most commonly in patients with extensive hepatic metastases. (See
         <a class="local">
          'Well-differentiated gastrointestinal neuroendocrine tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphoma may arise as a primary neoplasm in the intestinal tract or as a component of systemic disease with gastrointestinal involvement. Primary gastrointestinal tract lymphoma is the most common extranodal form of lymphoma; the lymphoid-rich ileum is the most common location. (See
         <a class="local">
          'Primary gastrointestinal tract lymphoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant mesenchymal tumors (sarcomas) represent approximately 10 percent of small bowel neoplasms and are most common in the jejunum and ileum. The most common type of intestinal sarcoma is gastrointestinal stromal tumor. (See
         <a class="local">
          'Sarcoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The frequency of benign tumors of the small bowel increases from the duodenum to the ileum. Villous adenomas carry a significant potential for malignant transformation. Patients with sporadic duodenal adenomas should be screened for colorectal cancer as they are at increased risk. (See
         <a class="local">
          'Adenomas'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3884811386">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges James Cusack Jr, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Weiss NS, Yang CP. Incidence of histologic types of cancer of the small intestine. J Natl Cancer Inst 1987; 78:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLaughlin PD, Maher MM. Primary malignant diseases of the small intestine. AJR Am J Roentgenol 2013; 201:W9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabos S, Berkel J, Band P, et al. Small bowel cancer in western Canada. Int J Epidemiol 1993; 22:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatzaras I, Palesty JA, Abir F, et al. Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the connecticut tumor registry. Arch Surg 2007; 142:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow JS, Chen CC, Ahsan H, Neugut AI. A population-based study of the incidence of malignant small bowel tumours: SEER, 1973-1990. Int J Epidemiol 1996; 25:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramanian KN, Ghosh PK, Dhar R, et al. The primary structure of regions of SV 40 DNA encoding the ends of mRNA. Prog Nucleic Acid Res Mol Biol 1976; 19:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghav K, Overman MJ. Small bowel adenocarcinomas--existing evidence and evolving paradigms. Nat Rev Clin Oncol 2013; 10:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiSario JA, Burt RW, Vargas H, McWhorter WP. Small bowel cancer: epidemiological and clinical characteristics from a population-based registry. Am J Gastroenterol 1994; 89:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lepage C, Bouvier AM, Manfredi S, et al. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol 2006; 101:2826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung CS, Tai CM, Huang TY, et al. Small bowel tumors: A digestive endoscopy society of Taiwan (DEST) multicenter enteroscopy-based epidemiologic study. J Formos Med Assoc 2018; 117:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeSesso JM, Jacobson CF. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol 2001; 39:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow WH, Linet MS, McLaughlin JK, et al. Risk factors for small intestine cancer. Cancer Causes Control 1993; 4:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Severson RK, Schenk M, Gurney JG, et al. Increasing incidence of adenocarcinomas and carcinoid tumors of the small intestine in adults. Cancer Epidemiol Biomarkers Prev 1996; 5:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haselkorn T, Whittemore AS, Lilienfeld DE. Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences. Cancer Causes Control 2005; 16:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neugut AI, Jacobson JS, Suh S, et al. The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarkers Prev 1998; 7:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scélo G, Boffetta P, Hemminki K, et al. Associations between small intestine cancer and other primary cancers: an international population-based study. Int J Cancer 2006; 118:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zar N, Garmo H, Holmberg L, Hellman P. Risk of second primary malignancies and causes of death in patients with adenocarcinoma and carcinoid of the small intestine. Eur J Cancer 2008; 44:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neugut AI, Santos J. The association between cancers of the small and large bowel. Cancer Epidemiol Biomarkers Prev 1993; 2:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler JM, Warren BF, Mortensen NJ, et al. An insight into the genetic pathway of adenocarcinoma of the small intestine. Gut 2002; 50:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perzin KH, Bridge MF. Adenomas of the small intestine: a clinicopathologic review of 51 cases and a study of their relationship to carcinoma. Cancer 1981; 48:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrock AB, Devoe CE, McWilliams R, et al. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol 2017; 3:1546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hänninen UA, Katainen R, Tanskanen T, et al. Exome-wide somatic mutation characterization of small bowel adenocarcinoma. PLoS Genet 2018; 14:e1007200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez-Bigas MA, Vasen HF, Lynch HT, et al. Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carcinoma. International Collaborative Group on HNPCC. Cancer 1998; 83:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang MQ, Chen ZM, Wang HL. Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma. Mod Pathol 2006; 19:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abrahams NA, Halverson A, Fazio VW, et al. Adenocarcinoma of the small bowel: a study of 37 cases with emphasis on histologic prognostic factors. Dis Colon Rectum 2002; 45:1496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawashima A, Goldman SM, Fishman EK, et al. CT of intraabdominal desmoid tumors: is the tumor different in patients with Gardner's disease? AJR Am J Roentgenol 1994; 162:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu AH, Yu MC, Mack TM. Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma. Int J Cancer 1997; 70:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cross AJ, Leitzmann MF, Subar AF, et al. A prospective study of meat and fat intake in relation to small intestinal cancer. Cancer Res 2008; 68:9274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen CC, Neugut AI, Rotterdam H. Risk factors for adenocarcinomas and malignant carcinoids of the small intestine: preliminary findings. Cancer Epidemiol Biomarkers Prev 1994; 3:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Negri E, Bosetti C, La Vecchia C, et al. Risk factors for adenocarcinoma of the small intestine. Int J Cancer 1999; 82:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjørge T, Tretli S, Engeland A. Height and body mass index in relation to cancer of the small intestine in two million Norwegian men and women. Br J Cancer 2005; 93:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samanic C, Gridley G, Chow WH, et al. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 2004; 15:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada A, Komaki Y, Komaki F, et al. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol 2018; 19:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Aliment Pharmacol Ther 2007; 25:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solem CA, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Small intestinal adenocarcinoma in Crohn's disease: a case-control study. Inflamm Bowel Dis 2004; 10:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004; 19:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green PH, Jabri B. Celiac disease and other precursors to small-bowel malignancy. Gastroenterol Clin North Am 2002; 31:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howdle PD, Jalal PK, Holmes GK, Houlston RS. Primary small-bowel malignancy in the UK and its association with coeliac disease. QJM 2003; 96:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green PH, Cellier C. Celiac disease. N Engl J Med 2007; 357:1731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heymann MF, Hamy A, Triau S, et al. Endocrine tumors of the duodenum. A study of 55 cases relative to clinicopathological features and hormone content. Hepatogastroenterology 2004; 51:1367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leoncini E, Carioli G, La Vecchia C, et al. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol 2016; 27:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciresi DL, Scholten DJ. The continuing clinical dilemma of primary tumors of the small intestine. Am Surg 1995; 61:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minardi AJ Jr, Zibari GB, Aultman DF, et al. Small-bowel tumors. J Am Coll Surg 1998; 186:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ojha A, Zacherl J, Scheuba C, et al. Primary small bowel malignancies: single-center results of three decades. J Clin Gastroenterol 2000; 30:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talamonti MS, Goetz LH, Rao S, Joehl RJ. Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 2002; 137:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DARLING RC, WELCH CE. Tumors of the small intestine. N Engl J Med 1959; 260:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia Marcilla JA, Sanchez Bueno F, Aguilar J, Parrilla Paricio P. Primary small bowel malignant tumors. Eur J Surg Oncol 1994; 20:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michelassi F, Testa G, Pomidor WJ, et al. Adenocarcinoma complicating Crohn's disease. Dis Colon Rectum 1993; 36:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch HT, Smyrk TC, Lynch PM, et al. Adenocarcinoma of the small bowel in lynch syndrome II. Cancer 1989; 64:2178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MOERTEL CG, SAUER WG, DOCKERTY MB, BAGGENSTOSS AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha S, Hoda S, Godfrey R, et al. Carcinoid tumors of the gastrointestinal tract: a 44-year experience. South Med J 1989; 82:1501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dabaja BS, Suki D, Pro B, et al. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004; 101:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 2010; 199:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross RK, Hartnett NM, Bernstein L, Henderson BE. Epidemiology of adenocarcinomas of the small intestine: is bile a small bowel carcinogen? Br J Cancer 1991; 63:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ribeiro MB, Greenstein AJ, Heimann TM, et al. Adenocarcinoma of the small intestine in Crohn's disease. Surg Gynecol Obstet 1991; 173:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Widmar M, Greenstein AJ, Sachar DB, et al. Small bowel adenocarcinoma in Crohn's disease. J Gastrointest Surg 2011; 15:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palascak-Juif V, Bouvier AM, Cosnes J, et al. Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis 2005; 11:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howe JR, Karnell LH, Menck HR, Scott-Conner C. The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer 1999; 86:2693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massironi S, Campana D, Partelli S, et al. Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. Ann Surg Oncol 2018; 25:3200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laskaratos FM, Rombouts K, Caplin M, et al. Neuroendocrine tumors and fibrosis: An unsolved mystery? Cancer 2017; 123:4770.
          </a>
         </li>
         <li class="breakAll">
          AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge, SB, Byrd, DR, Compton, CC, et al (Eds), Springer, New York 2010. p.181.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niederle B, Pape UF, Costa F, et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology 2016; 103:125.
          </a>
         </li>
         <li class="breakAll">
          Bergsland EK, Woltering EA, Rindi G, et al. Neuroendocrine tumors of the duodenum and ampulla of Vater. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.361.
         </li>
         <li class="breakAll">
          Woltering EA, Bergsland EK, Beyer DT, et al. Neuroendocrine tumors of the jejunum and ileum. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.375. Corrected at 4th printing, 2018.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 2017; 18:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Datta S, Williams N, Suortamo S, et al. Carcinoid syndrome from small bowel endocrine carcinoma in the absence of hepatic metastasis. Age Ageing 2011; 40:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldman JM, Jones RS. Carcinoid syndrome from gastrointestinal carcinoids without liver metastasis. Ann Surg 1982; 196:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haq AU, Yook CR, Hiremath V, Kasimis BS. Carcinoid syndrome in the absence of liver metastasis: a case report and review of literature. Med Pediatr Oncol 1992; 20:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DAWSON IM, CORNES JS, MORSON BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg 1961; 49:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper MJ, Williamson RC. Enteric adenoma and adenocarcinoma. World J Surg 1985; 9:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sweetenham JW, Mead GM, Wright DH, et al. Involvement of the ileocaecal region by non-Hodgkin's lymphoma in adults: clinical features and results of treatment. Br J Cancer 1989; 60:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001; 19:3861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domizio P, Owen RA, Shepherd NA, et al. Primary lymphoma of the small intestine. A clinicopathological study of 119 cases. Am J Surg Pathol 1993; 17:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turowski GA, Basson MD. Primary malignant lymphoma of the intestine. Am J Surg 1995; 169:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isaacson PG. Gastrointestinal lymphoma. Hum Pathol 1994; 25:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devaney K, Jaffe ES. The surgical pathology of gastrointestinal Hodgkin's disease. Am J Clin Pathol 1991; 95:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howe JR, Karnell LH, Scott-Conner C. Small bowel sarcoma: analysis of survival from the National Cancer Data Base. Ann Surg Oncol 2001; 8:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimizu N, Kuramoto S, Mimura T, et al. Leiomyosarcoma originating in Meckel's diverticulum: report of a case and a review of 59 cases in the English literature. Surg Today 1997; 27:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miettinen M, Kopczynski J, Makhlouf HR, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 2003; 27:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanchard DK, Budde JM, Hatch GF 3rd, et al. Tumors of the small intestine. World J Surg 2000; 24:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           FARMER RG, HAWK WA. METASTATIC TUMORS OF THE SMALL BOWEL. Gastroenterology 1964; 47:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadakia SC, Parker A, Canales L. Metastatic tumors to the upper gastrointestinal tract: endoscopic experience. Am J Gastroenterol 1992; 87:1418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richie RE, Reynolds VH, Sawyers JL. Tumor metastases to the small bowel from extra-abdominal sites. South Med J 1973; 66:1383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elsayed AM, Albahra M, Nzeako UC, Sobin LH. Malignant melanomas in the small intestine: a study of 103 patients. Am J Gastroenterol 1996; 91:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lens M, Bataille V, Krivokapic Z. Melanoma of the small intestine. Lancet Oncol 2009; 10:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kemp CD, Russell RT, Sharp KW. Resection of benign duodenal neoplasms. Am Surg 2007; 73:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witteman BJ, Janssens AR, Griffioen G, Lamers CB. Villous tumours of the duodenum. An analysis of the literature with emphasis on malignant transformation. Neth J Med 1993; 42:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seifert E, Schulte F, Stolte M. Adenoma and carcinoma of the duodenum and papilla of Vater: a clinicopathologic study. Am J Gastroenterol 1992; 87:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spigelman AD, Williams CB, Talbot IC, et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989; 2:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ASGE Standards of Practice Committee, Chathadi KV, Khashab MA, et al. The role of endoscopy in ampullary and duodenal adenomas. Gastrointest Endosc 2015; 82:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apel D, Jakobs R, Weickert U, Riemann JF. High frequency of colorectal adenoma in patients with duodenal adenoma but without familial adenomatous polyposis. Gastrointest Endosc 2004; 60:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider AR, Seifert H, Trojan J, et al. Frequency of colorectal polyps in patients with sporadic adenomas or adenocarcinomas of the papilla of vater--an age-matched, controlled study. Z Gastroenterol 2005; 43:1123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray MA, Zimmerman MJ, Ee HC. Sporadic duodenal adenoma is associated with colorectal neoplasia. Gut 2004; 53:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dudiak KM, Johnson CD, Stephens DH. Primary tumors of the small intestine: CT evaluation. AJR Am J Roentgenol 1989; 152:995.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2517 Version 51.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3470541" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Incidence of histologic types of cancer of the small intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19106677" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23789703" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Primary malignant diseases of the small intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8505174" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Small bowel cancer in western Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17372046" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the connecticut tumor registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8921448" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A population-based study of the incidence of malignant small bowel tumours: SEER, 1973-1990.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/190641" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The primary structure of regions of SV 40 DNA encoding the ends of mRNA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23897080" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Small bowel adenocarcinomas--existing evidence and evolving paradigms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8172140" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Small bowel cancer: epidemiological and clinical characteristics from a population-based registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17026561" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Incidence and management of primary malignant small bowel cancers: a well-defined French population study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28988888" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Small bowel tumors: A digestive endoscopy society of Taiwan (DEST) multicenter enteroscopy-based epidemiologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cancer statistics, 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11278053" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8481495" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Risk factors for small intestine cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8850266" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Increasing incidence of adenocarcinomas and carcinoid tumors of the small intestine in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16132788" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9521441" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The epidemiology of cancer of the small bowel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16003748" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Associations between small intestine cancer and other primary cancers: an international population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18207733" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Risk of second primary malignancies and causes of death in patients with adenocarcinoma and carcinoid of the small intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8268772" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The association between cancers of the small and large bowel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11788563" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : An insight into the genetic pathway of adenocarcinoma of the small intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7248908" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Adenomas of the small intestine: a clinicopathologic review of 51 cases and a study of their relationship to carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28617917" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Genomic Profiling of Small-Bowel Adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29522538" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Exome-wide somatic mutation characterization of small bowel adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9669805" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carcinoma. International Collaborative Group on HNPCC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16501564" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11113065" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Very high risk of cancer in familial Peutz-Jeghers syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12432298" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Adenocarcinoma of the small bowel: a study of 37 cases with emphasis on histologic prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8310922" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : CT of intraabdominal desmoid tumors: is the tumor different in patients with Gardner's disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9052748" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19010900" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A prospective study of meat and fat intake in relation to small intestinal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8019367" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Risk factors for adenocarcinomas and malignant carcinoids of the small intestine: preliminary findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10389747" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Risk factors for adenocarcinoma of the small intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16175183" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Height and body mass index in relation to cancer of the small intestine in two million Norwegian men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11227921" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A prospective study of obesity and cancer risk (Sweden).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14970733" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Obesity and cancer risk among white and black United States veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29706374" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17402989" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Meta-analysis: mortality in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15058524" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Small intestinal adenocarcinoma in Crohn's disease: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14984375" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12134621" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Celiac disease and other precursors to small-bowel malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12702783" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Primary small-bowel malignancy in the UK and its association with coeliac disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17960014" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Celiac disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15362754" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Endocrine tumors of the duodenum. A study of 55 cases relative to clinicopathological features and hormone content.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26487581" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7618809" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The continuing clinical dilemma of primary tumors of the small intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9632155" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Small-bowel tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10777190" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Primary small bowel malignancies: single-center results of three decades.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11982470" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13632900" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Tumors of the small intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7995411" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Primary small bowel malignant tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8348849" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Adenocarcinoma complicating Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2804907" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Adenocarcinoma of the small bowel in lynch syndrome II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13771655" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Life history of the carcinoid tumor of the small intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2595419" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Carcinoid tumors of the gastrointestinal tract: a 44-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15274064" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20609724" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A single-institution experience with 491 cases of small bowel adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1989654" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Epidemiology of adenocarcinomas of the small intestine: is bile a small bowel carcinogen?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1948581" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Adenocarcinoma of the small intestine in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21336499" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Small bowel adenocarcinoma in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16116317" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10594865" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28448665" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30054824" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29112233" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Neuroendocrine tumors and fibrosis: An unsolved mystery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29112233" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Neuroendocrine tumors and fibrosis: An unsolved mystery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26758972" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26758972" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26758972" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28238592" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21903639" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Carcinoid syndrome from small bowel endocrine carcinoma in the absence of hepatic metastasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7092350" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Carcinoid syndrome from gastrointestinal carcinoids without liver metastasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1574032" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Carcinoid syndrome in the absence of liver metastasis: a case report and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13884035" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4082613" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Enteric adenoma and adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2789943" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Involvement of the ileocaecal region by non-Hodgkin's lymphoma in adults: clinical features and results of treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11559724" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8470758" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Primary lymphoma of the small intestine. A clinicopathological study of 119 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7694986" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Primary malignant lymphoma of the intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8068936" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10577857" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7927306" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Gastrointestinal lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2042588" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The surgical pathology of gastrointestinal Hodgkin's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11456049" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Small bowel sarcoma: analysis of survival from the National Cancer Data Base.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9306549" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Leiomyosarcoma originating in Meckel's diverticulum: report of a case and a review of 59 cases in the English literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12717247" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10706914" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Tumors of the small intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14226219" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : METASTATIC TUMORS OF THE SMALL BOWEL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1415098" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Metastatic tumors to the upper gastrointestinal tract: endoscopic experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4586467" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Tumor metastases to the small bowel from extra-abdominal sites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8633538" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Malignant melanomas in the small intestine: a study of 103 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19410196" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Melanoma of the small intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18092639" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Resection of benign duodenal neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8446225" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Villous tumours of the duodenum. An analysis of the literature with emphasis on malignant transformation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1728122" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Adenoma and carcinoma of the duodenum and papilla of Vater: a clinicopathologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2571019" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Upper gastrointestinal cancer in patients with familial adenomatous polyposis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26260385" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : The role of endoscopy in ampullary and duodenal adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15332030" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : High frequency of colorectal adenoma in patients with duodenal adenoma but without familial adenomatous polyposis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16220451" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Frequency of colorectal polyps in patients with sporadic adenomas or adenocarcinomas of the papilla of vater--an age-matched, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14724161" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Sporadic duodenal adenoma is associated with colorectal neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2705358" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Primary tumors of the small intestine: CT evaluation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
